Recent Updates
Recently added Catalysts
INCR Neutral Sentiment Score: 50/100

InterCure Announces Reschedules 2022 Full Year Results Conference Call NEW YORK, TORONTO, and

Key Takeaway: InterCure Ltd. has announced the rescheduling of its conference call to discuss the financial results for the year ended December 31, 2022. Originally planned for April 3, 2023, the call will now take place on April 4, 2023, at 4:30 P.M. Eastern time. The postponement is attributed to unforeseen technical issues. InterCure is recognized as a leading cannabis company, emphasizing its growth within the international market.

Market Sentiment Analysis

POSITIVE FACTORS

  • InterCure is a leading and profitable cannabis company outside of North America.
  • The company operates Israel's largest licensed cannabis production facility.
  • InterCure leverages a high-margin 'seed-to-sale' business model.

CONCERNS & RISKS

  • The conference call was rescheduled due to unforeseen technical issues.
  • The ongoing need to communicate changes in scheduling may imply management challenges.

Full Press Release Details

Announces Reschedules 2022 Full Year Results Conference Call
YORK, TORONTO, and HERZLIYA, Israel - April 3, 2023 - InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR)
(dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced
conference call to discuss the company's financial results for the full year ended December 31, 2022.
call was originally scheduled for April 3, 2023 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, 2023 at 4:30 P.M. (Eastren
time) due to unforeseen circumstances which caused technical issues.
can access the live webcast and conference call through the following link:
InterCure (dba Canndoc)
(dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North
America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to
offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international
market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale"
model to lead the fastest growing cannabis global market outside of North America.
more information, visit: http://www.intercure.co.
Cohen, Chief Financial Officer

Frequently Asked Questions

When is InterCure's rescheduled conference call?

The rescheduled conference call is on April 4, 2023, at 4:30 P.M. Eastern time.

Why was the conference call rescheduled?

The call was rescheduled due to unforeseen circumstances causing technical issues.

How can I access the conference call?

You can access the call via the live webcast link provided in the announcement.

What is InterCure's primary business?

InterCure, through Canndoc, is a leading cannabis producer licensed in Israel.

What sets Canndoc apart in the cannabis industry?

Canndoc is notable for its GMP-certified, pharmaceutical-grade medical cannabis products.

Last updated: Apr 3, 2023